Bicycle Therapeutics PLC Sponsored ADR

BCYC

Healthcare Biotechnology

Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024.

Revenue
+190.2%
EPS
+82.4%
Free cash flow
+43.5%

Quarter to September 2026, against a year earlier

3.61 0.13 +3.74%
Market cap
$182.5M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
2/9
ROIC
−279.8%
Net debt / EBITDA
2.6×
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
3.08 4.84 5.09 6.76
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(6.39) (5.97) (4.90) (25.35)
P/B ratio
0.51 0.58 0.58 0.80
EV/Sales
(2.29) (3.15) (3.39) (1.61)
EV/EBITDA
1.25 0.94 0.91 0.48
EV/FCF
1.08 0.93 0.93 0.46
Current Ratio
12.09 12.08 12.66 11.98
Net Debt/EBITDA
37.89 9.54 8.69 26.87
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(55.15%) (64.39%) (67.89%) (44.63%)
Free Cash Flow Yield
(68.74%) (70.37%) (71.66%) (51.38%)
Free Cash Flow per Share
(0.58) (0.71) (0.96) (0.29)
Book value per Share
7.22 7.31 7.95 8.80
Free Cash Flow
(40.61) (49.87) (66.64) (19.92)
EV/EBIT
1.21 0.92 0.89 0.47
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026